Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Luye Pharma Group Ltd.
  6. Summary
    2186   BMG570071099

LUYE PHARMA GROUP LTD.

(2186)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
06/18/2021 06/21/2021 06/22/2021 06/23/2021 06/24/2021 Date
5.25 5.2 5.22 5.22 5.2 Last
13298230 19430510 17121000 18294400 12791620 Volume
+1.35% -0.95% +0.38% 0.00% -0.38% Change
Estimated financial data (e)
Sales 2021 5 924 M 916 M 916 M
Net income 2021 953 M 147 M 147 M
Net Debt 2021 2 170 M 335 M 335 M
P/E ratio 2021 19,9x
Yield 2021 0,73%
Sales 2022 6 928 M 1 071 M 1 071 M
Net income 2022 1 210 M 187 M 187 M
Net Debt 2022 1 483 M 229 M 229 M
P/E ratio 2022 16,8x
Yield 2022 0,89%
Capitalization 18 415 M 2 372 M 2 846 M
EV / Sales 2021 3,48x
EV / Sales 2022 2,87x
Nbr of Employees 4 963
Free-Float 64,1%
More Financials
Company
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include... 
Sector
Pharmaceuticals
Calendar
08/30Earnings Release
More about the company
Ratings of Luye Pharma Group Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about LUYE PHARMA GROUP LTD.
06/15LUYE PHARMA  : Subsidiary Seeks US FDA Nod to Start Phase II Study of COVID-19 A..
MT
06/11LUYE PHARMA  : Chinese Regulators Accept Luye Pharma's Marketing Application for..
MT
05/27LUYE PHARMA  : Unit Grants AstraZeneca Exclusive Promotion Rights to Cancer Drug..
MT
05/24LUYE PHARMA  : EU Grants Marketing Authorization to Luye Pharma's Transdermal Pa..
MT
05/14LUYE PHARMA  : Form of proxy for use at annual general meeting to be held on 16 ..
PU
05/13LUYE PHARMA  : Notice of annual general meeting
PU
05/13LUYE PHARMA  : Proposals for general mandates to issue shares and repurchase sha..
PU
05/13LUYE PHARMA  : Voluntary announcement - approval obtained for initiating clinica..
PU
05/12LUYE PHARMA  : Wins Regulatory Nod to Start Anesthesia's Clinical Trial in China
MT
05/07LUYE PHARMA  : Voluntary announcement - approval for initiating clinical trial f..
PU
05/07LUYE PHARMA  : Unit Wins Marketing Registration Approval for Cancer Drug in Chin..
MT
05/07LUYE PHARMA  : Unit Wins Regulatory Nod to Start Cancer Drug's Clinical Trial in..
MT
05/06LUYE PHARMA  : VOLUNTARY ANNOUNCEMENT - NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2..
PU
05/05LUYE PHARMA  : Unit Completes Phase I Clinical Trial of COVID-19 Vaccine in Chin..
MT
03/25LUYE PHARMA  : Phase 3 Study of Antidepressant Meets Efficacy Endpoints; Shares ..
MT
More news
News in other languages on LUYE PHARMA GROUP LTD.
2017Dietmar Hopp se prépare à vendre les patches LTS-sources
More news
Chart LUYE PHARMA GROUP LTD.
Duration : Period :
Luye Pharma Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUYE PHARMA GROUP LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 5,20 CNY
Average target price 4,95 CNY
Spread / Average Target -4,88%
EPS Revisions
Managers and Directors
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Rong Bing Yang Vice Executive Chairman & President
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hua Qiao Zhang Independent Non-Executive Director
Sector and Competitors